Shots:
- Roche has received 510(k) clearance with CLIA waiver & CE-IVDR certification for its point-of-care test to diagnose whooping cough (pertussis) & other Bordetella infections
- The PCR test on the cobas liat system delivers results in 15min. in GP clinics & emergency rooms, allowing real-time diagnosis during consultation & supporting immediate antibiotic decisions to help prevent complications & transmission
- The test detects & distinguishes between 3 Bordetella species: B. pertussis (whooping cough), B. parapertussis (a milder pertussis-like illness with variable treatment response), & B. holmesii (an emerging pathogen linked with pertussis-like symptoms), supporting more accurate diagnosis & management
Ref: Roche | Image: Roche | Press Release
Related News: Genentech (Roche) Reports Interim P-III (lidERA Breast Cancer) Trial Data on Giredestrant for Early Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
